KDMN News and Press, Kadmon Holdings Inc. From 11/01/18

NEW YORK, Nov. 01, 2018 (GLOBE NEWSWIRE) -- Kadmon Holdings, Inc. (NYSE: KDMN) today announced that updated data from its ongoing Phase 2 clinical trial evaluating KD025 for the treatment of chronic graft-versus-host disease (cGVHD) have been selected for oral presentation at the 60 th Ame...

Shares of Kadmon Holdings ( KDMN ) have lost a third of their value since I wrote my ASH update piece last year. In the article, I noted that new clinical results from a mid-stage study evaluating Rho-associated coiled-coil kinase 2 (ROCK2) inhibitor KD025 in patients with chronic graft-ve...

NEW YORK, Oct. 25, 2018 (GLOBE NEWSWIRE) -- Kadmon Holdings, Inc. (NYSE: KDMN) today announced that the first patient has been dosed in a pivotal clinical trial of KD025 in chronic graft-versus-host disease (cGVHD). The study will evaluate the efficacy and safety of KD025, Kadmon’s R...

NEW YORK, Oct. 24, 2018 (GLOBE NEWSWIRE) -- Kadmon Holdings, Inc. (NYSE: KDMN) today announced that Konstantin Poukalov has notified the company of his intent to step down as Executive Vice President, Chief Financial Officer (CFO) and Principal Accounting Officer (PAO), effective immediatel...

NEW YORK, Oct. 18, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Control4 Corporation (NASDAQ:CTRL), REGENXBIO Inc. (NASDAQ:RGNX), Ferr...

Kadmon Holdings (NYSE: KDMN ) is up  7%  premarket on light volume following its announcement that the FDA has designated KD025 a Breakthrough Therapy for the treatment of patients with chronic graft-versus-host disease (cGVHD) who have failed to respond to two or more prior line...

AzurRx BioPharma (NASDAQ: AZRX ) initiated with Outperform rating and $6 (140% upside) price target at Oppenheimer. Shares up  8%  premarket. More news on: AzurRX Biopharma, Bio-Techne Corp., Bio-Rad Laboratories, Inc., Healthcare stocks news, Stocks on the move, , Read more ...

NEW YORK, Oct. 17, 2018 (GLOBE NEWSWIRE) -- Kadmon Holdings, Inc. (NYSE: KDMN) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to KD025, the company’s ROCK2 inhibitor, for the treatment of patients with chronic graft-versu...